COSMOS Pharmaceutical Corporation (3349.T)

Positive revenue growth while 9843.T is negative. John Neff might see a notable competitive edge here.

Positive gross profit growth while 9843.T is negative. John Neff would see a clear operational edge over the competitor.

Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.

Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.

Positive net income growth while 9843.T is negative. John Neff might see a big relative performance advantage.

Positive EPS growth while 9843.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.

Positive diluted EPS growth while 9843.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.

Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.

Dividend growth of 15.38% while 9843.T is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.

10Y revenue/share CAGR above 1.5x 9843.T's 77.56%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.

5Y revenue/share CAGR 1.25-1.5x 9843.T's 26.52%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.

Positive 3Y CAGR while 9843.T is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.

Positive 10Y CAGR while 9843.T is negative. John Neff might see a substantial advantage in bottom-line trajectory.

Positive 5Y CAGR while 9843.T is negative. John Neff might view this as a strong mid-term relative advantage.

Positive short-term CAGR while 9843.T is negative. John Neff would see a clear advantage in near-term profit trajectory.

10Y equity/share CAGR above 1.5x 9843.T's 185.48%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.

5Y equity/share CAGR above 1.5x 9843.T's 50.09%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.

3Y equity/share CAGR above 1.5x 9843.T's 7.70%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.

10Y dividend/share CAGR above 1.5x 9843.T's 153.33%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.

5Y dividend/share CAGR above 1.5x 9843.T's 31.03%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.

3Y dividend/share CAGR above 1.5x 9843.T's 5.56%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.

Inventory shrinking or stable vs. 9843.T's 15.58%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.

Asset growth above 1.5x 9843.T's 1.54%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.

BV/share growth above 1.5x 9843.T's 1.40%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.

We have some new debt while 9843.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.

No Data available this quarter, please select a different quarter.